trial

Efficacy of Lu 31-130 in Patients With Schizophrenia

NCTId NCT00768326
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 280 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2009-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
280 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-03
Primary completion
2009-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Zicronapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

1 total
Munich, Germany

Linked catalysts

1
Efficacy of Lu 31-130 in Patients With Schizophrenia — primary completion2009-10

Facts & assertions

4 sourced
Enrollment
280
Phase
PHASE2
Primary Completion Date
2009-10
Status
COMPLETED
relationships
The graph out of here
drug
Zicronapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication